Beijing Deda Biopharmaceutical

Beijing Deda Biopharmaceutical is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses on addressing unmet medical needs in oncology and metabolic diseases by targeting complex biological mechanisms such as protein-protein interactions and the ubiquitin-proteasome system. Its lead program, DEDA-111, is a highly selective inhibitor of Ubiquitin-specific protease 7 (USP7) currently in Phase 1 clinical trials for the treatment of advanced solid tumors. Deda Biopharmaceutical utilizes a proprietary drug discovery platform to generate a diverse pipeline of first-in-class and best-in-class candidates. The firm is supported by a team of experienced scientists and has secured investment from prominent venture capital firms to advance its clinical and preclinical assets.